863885-81-8

Basic information

• Product Name: 2-Propenoic acid, 3-(2-ethoxy-4-nitrophenyl)-, methyl ester, (2E)-
• CAS NO: 863885-81-8
• Molecular Formula: C12H13NO5
• Molecular Weight: 251.239
• Mol File: 863885-81-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3-(2-ethoxy-4-nitrophenyl)-, methyl ester, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-(2-ethoxy-4-nitrophenyl)-, methyl ester, (2E)-(863885-81-8)
• EPA Substance Registry System: 2-Propenoic acid, 3-(2-ethoxy-4-nitrophenyl)-, methyl ester, (2E)-(863885-81-8)

Safety Data

• Hazardous Substances Data: 863885-81-8(Hazardous Substances Data)

Upstream product

• 10473-47-9 2-Ethoxy-4-nitro-benzylalkohol 
• 2486-66-0 2-ethoxy-4-nitrobenzoic acid 
• 5927-18-4 trimethyl phosphonoacetate 
• 1134-43-6 2-ethoxy-4-nitro-benzaldehyde 
• 24630-57-7 O,O-dimethylacetoxymethylphosphonate 

Downstream Products

• 874676-76-3 (E)-3-{4-[(1-aminocyclobutanecarbonyl)amino]-2-ethoxyphenyl}acrylic acid methyl ester 
• 874676-77-4 C₃₇H₄₀N₄O₅ 
• 863885-82-9 C₁₂H₁₂N₂O₇ 

Relevant articles and documents

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection

The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, 27) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (1). Cell-based replicon potency was significantly improved through electronic modulation of the pKa of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to 27, a predicted low clearance compound in man. The preclinical profile of inhibitor 27 is discussed, as well as the identification of a genotoxic metabolite that led to the discontinuation of the development of this compound.

VIRAL POLYMERASE INHIBITORS

An enantiomer, diastereoisomer or tautomer of a compound, represented by formula (I): wherein either A or B is nitrogen and the other B or A is C, and the radicals R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof as viral polymerase inhibitors. The compound is used as an inhibitor of RNA dependent RNA polymerases, particularly those viral polymerases within the Flaviviridae family, more particularly to HCV polymerase.